Skip to main content
. 2023 Sep 11;13:1248690. doi: 10.3389/fonc.2023.1248690

Table 4.

Adverse events during treatment in 68 patients.

Adverse events Grade 1-2 Grade 3
Control group Study group Control group Study group Total (%)
Oral ulcers 3 2 0 0 5 (7.6%)
Rash 8 7 0 0 15 (22.1%)
Diarrhea 1 4 1 0 6 (8.8%)
Nausea 1 3 2 0 6 (8.8%)
Myelosuppression 3 9 0 7 19 (27.9%)
Hepatotoxicity 0 6 0 0 6 (8.8%)
increased CK 5 7 0 0 12 (17.6%)
Fatigue 1 2 0 0 3 (4.4%)
Decreased appetite 1 4 0 0 5 (7.4%)